Evaluate Vantage Homepage


Company Events

Vantage logo

Biotech’s near-term key catalysts

Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.


Vantage logo

Pepgen aims to overtake Sarepta

Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.

Vantage logo

T3D puts a bet on Alzheibetes

An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.